Literature DB >> 22573477

Phenotype-optimized sequence ensembles substantially improve prediction of disease-causing mutation in cystic fibrosis.

David L Masica1, Patrick R Sosnay, Garry R Cutting, Rachel Karchin.   

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) mutation is associated with a phenotypic spectrum that includes cystic fibrosis (CF). The disease liability of some common CFTR mutations is known, but rare mutations are seen in too few patients to categorize unequivocally, making genetic diagnosis difficult. Computational methods can predict the impact of mutation, but prediction specificity is often below that required for clinical utility. Here, we present a novel supervised learning approach for predicting CF from CFTR missense mutation. The algorithm begins by constructing custom multiple sequence alignments called phenotype-optimized sequence ensembles (POSEs). POSEs are constructed iteratively, by selecting sequences that optimize predictive performance on a training set of CFTR mutations of known clinical significance. Next, we predict CF disease liability from a different set of CFTR mutations (test-set mutations). This approach achieves improved prediction performance relative to popular methods recently assessed using the same test-set mutations. Of clinical significance, our method achieves 94% prediction specificity. Because databases such as HGMD and locus-specific mutation databases are growing rapidly, methods that automatically tailor their predictions for a specific phenotype may be of immediate utility. If the performance achieved here generalizes to other systems, the approach could be an excellent tool to help establish genetic diagnoses.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573477      PMCID: PMC4364283          DOI: 10.1002/humu.22110

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  49 in total

1.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

2.  Newborn screening: toward a uniform screening panel and system--executive summary.

Authors: 
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

Review 3.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

4.  Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators. Interaction between activation and inhibition.

Authors:  Olga Zegarra-Moran; Martino Monteverde; Luis J V Galietta; Oscar Moran
Journal:  J Biol Chem       Date:  2007-01-23       Impact factor: 5.157

5.  Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator.

Authors:  A Vankeerberghen; L Wei; M Jaspers; J J Cassiman; B Nilius; H Cuppens
Journal:  Hum Mol Genet       Date:  1998-10       Impact factor: 6.150

6.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

7.  Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.

Authors:  H A Lewis; C Wang; X Zhao; Y Hamuro; K Conners; M C Kearins; F Lu; J M Sauder; K S Molnar; S J Coales; P C Maloney; W B Guggino; D R Wetmore; P C Weber; J F Hunt
Journal:  J Mol Biol       Date:  2009-11-26       Impact factor: 5.469

8.  Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces.

Authors:  J-P Mornon; P Lehn; I Callebaut
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

9.  Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Authors:  Adrian W R Serohijos; Tamás Hegedus; Andrei A Aleksandrov; Lihua He; Liying Cui; Nikolay V Dokholyan; John R Riordan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-27       Impact factor: 11.205

10.  Application of DETECTER, an evolutionary genomic tool to analyze genetic variation, to the cystic fibrosis gene family.

Authors:  Eric A Gaucher; Danny W De Kee; Steven A Benner
Journal:  BMC Genomics       Date:  2006-03-07       Impact factor: 3.969

View more
  11 in total

1.  Gene-specific features enhance interpretation of mutational impact on acid α-glucosidase enzyme activity.

Authors:  Aashish N Adhikari
Journal:  Hum Mutat       Date:  2019-08-07       Impact factor: 4.878

2.  Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.

Authors:  Lucia Guidugli; Hermela Shimelis; David L Masica; Vernon S Pankratz; Gary B Lipton; Namit Singh; Chunling Hu; Alvaro N A Monteiro; Noralane M Lindor; David E Goldgar; Rachel Karchin; Edwin S Iversen; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2018-01-25       Impact factor: 11.025

3.  PON-P and PON-P2 predictor performance in CAGI challenges: Lessons learned.

Authors:  Abhishek Niroula; Mauno Vihinen
Journal:  Hum Mutat       Date:  2017-05-02       Impact factor: 4.878

4.  Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.

Authors:  David L Masica; Patrick R Sosnay; Karen S Raraigh; Garry R Cutting; Rachel Karchin
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

5.  Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Authors:  David L Masica; Shuli Li; Christopher Douville; Judith Manola; Robert L Ferris; Barbara Burtness; Arlene A Forastiere; Wayne M Koch; Christine H Chung; Rachel Karchin
Journal:  Hum Genet       Date:  2014-08-10       Impact factor: 4.132

Review 6.  Towards Increasing the Clinical Relevance of In Silico Methods to Predict Pathogenic Missense Variants.

Authors:  David L Masica; Rachel Karchin
Journal:  PLoS Comput Biol       Date:  2016-05-12       Impact factor: 4.475

7.  The role of balanced training and testing data sets for binary classifiers in bioinformatics.

Authors:  Qiong Wei; Roland L Dunbrack
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

8.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Authors:  Patrick R Sosnay; Karen R Siklosi; Fredrick Van Goor; Kyle Kaniecki; Haihui Yu; Neeraj Sharma; Anabela S Ramalho; Margarida D Amaral; Ruslan Dorfman; Julian Zielenski; David L Masica; Rachel Karchin; Linda Millen; Philip J Thomas; George P Patrinos; Mary Corey; Michelle H Lewis; Johanna M Rommens; Carlo Castellani; Christopher M Penland; Garry R Cutting
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

9.  Assessing the correlation between mutant rhodopsin stability and the severity of retinitis pigmentosa.

Authors:  Richard McKeone; Matthew Wikstrom; Christina Kiel; P Elizabeth Rakoczy
Journal:  Mol Vis       Date:  2014-02-07       Impact factor: 2.367

Review 10.  The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health.

Authors:  Audrey C Woerner; Renata C Gallagher; Jerry Vockley; Aashish N Adhikari
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.